Judd W. Moul, MD

In this companion article, Judd W. Moul, MD, of Duke University Medical Center, shares expert insights into factors affecting treatment decisions in metastatic hormone-sensitive and castration-resistant prostate cancer.

In the first interview of the series, Judd W. Moul, MD, provides an overview of the management of mHSPC and mCRPC including key considerations in the use of the androgen deprivation therapy leuprolide with or without novel hormone therapy or chemotherapy.

Judd W. Moul, MD, FACS, wraps up by discussing remaining unmet needs and potential future improvements in imaging modalities for prostate cancer screening.

An expert urologic oncologist revisits a patient profile and discusses how he would have approached the patient’s prostate cancer screening process.

Judd W. Moul, MD, FACS, gives a real-world overview of how the exosome-based test is used in clinical practice.

An overview of the clinical validity and utility of a urine-based, exosomal molecular test for prostate cancer screening and risk assessment.

Judd W. Moul, MD, FACS, provides insight into the timing of biomarker testing in the prostate cancer screening process, and discusses which patients might benefit the most from testing.

Judd W. Moul, MD, FACS, introduces available blood- and urine-based biomarker tests for prostate cancer screening, and discusses how they might overcome limitations of commonly used modalities.

A focused discussion on the use of tools such as digital rectal exam, prostate biopsy, and MRI in prostate cancer diagnosis, staging, and grading.

Judd W. Moul, MD, FACS, reviews challenges of early detection of prostate cancer, and strategies to mitigate them.

A commentary on increasing trends in prostate cancer incidence and how many patients typically present with severe disease.

Judd W. Moul, MD, FACS, introduces the patient profile and discusses typical characteristics of patients undergoing prostate cancer screening in his practice.

Judd W. Moul, MD discusses data on real-world effectiveness and treatment adherence of apalutamide in non-metastatic castration-resistant prostate cancer patients that was presented at the American Urological Association 2021 Annual Meeting.

This article features insights from David Albala, MD, and Judd W. Moul, MD, on using liquid biomarker-based testing for the early detection of prostate cancer.

Expert urologists remark on unmet needs in prostate cancer by emphasizing the importance of reaching under-served communities, addressing patient discomfort, increasing education about liquid biopsy testing, and standardizing prostate size assessment.

Key opinion leaders in urology review factors to consider when selecting screening and risk-assessment tests for the diagnosis of prostate cancer including insurance coverage, commercial availability, and patient preference.

David Albala, MD and Judd W. Moul, MD consider the impact that COVID-19 has had on the clinical experience of patients with prostate cancer and share personal insights regarding telehealth and patient compliance.

Two experts in the management of prostate cancer provide key insight into the value of blood and urine liquid biopsy tests when deciding whether to perform a prostate tissue biopsy.

Thought leaders in the management of prostate cancer build a discussion on the challenges associated with the use of MRI to diagnose prostate cancer including insurance coverage and patient discomfort.

Experts urologists, David Albala, MD and Judd W. Moul, MD, compare the utility of a variety of blood and urine tests for screening and diagnosing prostate cancer.

Key opinion leaders in urology provide an overview of the prevalence of prostate cancer and discuss the importance of screening and risk assessment tools like the Prostate-Specific Antigen (PSA) test.

Dr Raoul Concepcion leads a panel discussion on a case of a 64-year-old man with multifocal prostate cancer treated with IMRT who refused ADT. 

Munir Ghesani, MD, an expert in nuclear medicine, describes the factors that differentiate available tracers and provides guidance on tracer selection. 

An expert panel reacts to polling data on choice of imaging modalities for patients with prostate patients after definitive therapy and share their insights about best practices.  

Raoul Concepcion, MD, presents the case of a 58-year-old man who had a radical prostatectomy 6 months prior and discusses how aspects of the case influence treatment selection. 

Experts in prostate cancer discuss considerations for initiating ADT therapy after definitive treatment in patients with prostate cancer in the context of biochemical recurrence. 

Brian Helfand, MD, PhD, describes the ways in which the PSA nadir can be defined after definitive therapy and the implications of the definition used for patients with prostate cancer. 

Dr Judd Moul and colleagues discuss best practices for monitoring patients with prostate cancer after definitive therapy. 

Dr Raoul Concepcion leads a panel of experts in prostate cancer in setting the stage for case-based discussions of biochemical recurrence.